Search Results - "Carpeño, Javier De Castro"

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis by Cejas, Paloma, López-Gómez, Miriam, Aguayo, Cristina, Madero, Rosario, de Castro Carpeño, Javier, Belda-Iniesta, Cristóbal, Barriuso, Jorge, Moreno García, Víctor, Larrauri, Javier, López, Rocío, Casado, Enrique, Gonzalez-Barón, Manuel, Feliu, Jaime

“…KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients…”
Get full text

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer by Blackhall, Fiona, Ross Camidge, D, Shaw, Alice T, Soria, Jean-Charles, Solomon, Benjamin J, Mok, Tony, Hirsh, Vera, Jänne, Pasi A, Shi, Yuankai, Yang, Pan-Chyr, Pas, Tommaso De, Hida, Toyoaki, Carpeño, Javier De Castro, Lanzalone, Silvana, Polli, Anna, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Kim, Dong-Wan

“…PurposeCrizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced…”
Get full text

ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications by SERENO, Maria, CEJAS, Paloma, MORENO, Víctor, BELDA-INIESTA, Cristóbal, LOPEZ, Rocio, NISTAL, Manuel, FELIU, Jaime, CASTRO CARPENO, Javier De

“…Small cell lung cancer is the most aggressive lung cancer subtype. The standard treatment approach is based on cisplatin regimens. Although response rates to…”
Get full text

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer by Gutierrez-Sainz, Laura, Cruz-Castellanos, Patricia, Higuera, Oliver, de Castro-Carpeño, Javier

“…Opinion statement Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of…”
Get full text

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients by Sanchez-Cabrero, Darío, Garcia-Guede, Álvaro, Burdiel, Miranda, Pernía, Olga, Colmenarejo-Fernandez, Julián, Gutierrez, Laura, Higuera, Oliver, Rodriguez, Isabel Esteban, Rosas-Alonso, Rocío, Rodriguez-Antolín, Carlos, Losantos-García, Itsaso, Vera, Olga, De Castro-Carpeño, Javier, Ibanez de Caceres, Inmaculada

“…Despite advances in non-small cell lung cancer (NSCLC) research, this is still the most common cancer type that has been diagnosed up to date. microRNAs have…”
Get full text

Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy by Guijarro-Eguinoa, Javier, Arjona-Hernandez, Sara, Stewart, Stefan, Pernia, Olga, Arias, Pedro, Losantos-García, Itsaso, Rubio, Tania, Burdiel, Miranda, Rodriguez-Antolin, Carlos, Cruz-Castellanos, Patricia, Higuera, Oliver, Borobia, Alberto M, Rodriguez-Novoa, Sonia, de Castro-Carpeño, Javier, Ibanez de Caceres, Inmaculada, Rosas-Alonso, Rocio

“…Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major…”
Get full text

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe by Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan

“…First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall…”
Get full text

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database by Campos‐Balea, Begoña, Castro Carpeño, Javier, Massutí, Bartomeu, Vicente‐Baz, David, Pérez Parente, Diego, Ruiz‐Gracia, Pedro, Crama, Leonardo, Cobo Dols, Manuel

“…Background Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for…”
Get full text

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer by Montalbán-Hernández, Karla, Casalvilla-Dueñas, José Carlos, Cruz-Castellanos, Patricia, Gutierrez-Sainz, Laura, Lozano-Rodríguez, Roberto, Avendaño-Ortiz, José, Del Fresno, Carlos, de Castro-Carpeño, Javier, López-Collazo, Eduardo

“…Lung cancer (LC) continues to be the leading cause of cancer-related deaths in both men and women worldwide. After complete tumour resection, around half of…”
Get full text

Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells by Belda-Iniesta, Cristóbal, Perona, Rosario, de Castro Carpeño, Javier, Cejas, Paloma, Casado, Enrique, Manguan-García, Cristina, Ibanez de Caceres, Inmaculada, Sanchez-Perez, Isabel, Bernabeu Andreu, Francisco, Alves Ferreira, Javier, Aguilera, Alfredo, de la Peña, Javier, Perez-Sánchez, Elia, Madero, Rosario, Feliu, Jaime, Sereno, María, González-Barón, Manuel

“…Human recombinant erythropoietin (hrEPO) therapy might be associated with tumor progression and death. This effect has been suggested to be secondary to rhEPO…”
Get full text

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC by Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Faivre-Finn, Corinne, Reck, Martin, Vansteenkiste, Johan, Spigel, David R, Wadsworth, Catherine, Melillo, Giovanni, Taboada, Maria, Dennis, Phillip A, Özgüroğlu, Mustafa

“…In patients with locally advanced non–small-cell lung cancer who have undergone concurrent chemotherapy and radiation therapy, the use of durvalumab in the…”
Get full text

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer by Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A, Özgüroğlu, Mustafa

“…Relapse is common in patients with locally advanced unresectable lung cancer after concurrent chemotherapy and radiation therapy. In a randomized study,…”
Get full text

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial by Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, Cruz-Bermúdez, Alberto

“…Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of…”
Get full text

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis by Antonia, Scott J, Borghaei, Hossein, Ramalingam, Suresh S, Horn, Leora, De Castro Carpeño, Javier, Pluzanski, Adam, Burgio, Marco A, Garassino, Marina, Chow, Laura Q M, Gettinger, Scott, Crinò, Lucio, Planchard, David, Butts, Charles, Drilon, Alexander, Wojcik-Tomaszewska, Joanna, Otterson, Gregory A, Agrawal, Shruti, Li, Ang, Penrod, John R, Brahmer, Julie

“…Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab…”
Get full text

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy by Casarrubios, Marta, Cruz-Bermúdez, Alberto, Nadal, Ernest, Insa, Amelia, García Campelo, María Del Rosario, Lázaro, Martín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, de Castro-Carpeño, Javier, Cobo, Manuel, López-Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Barquín, Miguel, Laza-Briviesca, Raquel, Sierra-Rodero, Belén, Parra, Edwin R, Sanchez-Espiridion, Beatriz, Rocha, Pedro, Kadara, Humam, Wistuba, Ignacio I, Romero, Atocha, Calvo, Virginia, Provencio, Mariano

“…Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally…”
Get full text

Cancer and acute cardiovascular diseases: team work to transform the clinical practice by López-Fernández, Teresa, de Castro Carpeño, Javier

Get full text

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study by Moro-Sibilot, Denis, Smit, Egbert, de Castro Carpeño, Javier, Lesniewski-Kmak, Krzysztof, Aerts, Joachim, Villatoro, Rosa, Kraaij, Kees, Nacerddine, Karim, Dyachkova, Yulia, Smith, Karen T, Taipale, Kaisa, Girvan, Allicia C, Visseren-Grul, Carla, Schnabel, Philipp A

“…Highlights • FRAME was a prospective observational study conducted across 11 countries in Europe. • 1564 NSCLC patients initiating FLT between 2009 and 2011…”
Get full text

The impact of next-generation sequencing on the DNA methylation–based translational cancer research by Soto, Javier, Rodriguez-Antolin, Carlos, Vallespín, Elena, de Castro Carpeño, Javier, Ibanez de Caceres, Inmaculada

“…Epigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired…”
Get full text

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors by Hurtado, Felipe K., de Braud, Filippo, De Castro Carpeño, Javier, de Miguel Luken, Maria Jose, Wang, Ding, Scott, Jeffrey, Lau, Yvonne Y., McCulloch, Tracey, Mau-Sorensen, Morten

“…Purpose Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients with ALK  + metastatic non-small…”
Get full text

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer by Nadal, Ernest, Oré-Arce, Martín, Remon, Jordi, Bernabé-Caro, Reyes, Covela-Rúa, Marta, de Castro-Carpeño, Javier, Massutí-Sureda, Bartomeu, Guillot-Morales, Mónica, Majem, Margarita, Maestu-Maiques, Inmaculada, Morilla-Ruíz, Idoia, Gironés, Regina

“…Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and…”
Get full text